drugset / Trial / NCT00840398
Buspirone Hydrochloride 30mg Tablets, Non-Fasting
RandomizedCrossoverOpen-labelOther
Summary
This study will compare the relative bioavailability (rate and extent of absorption) of 30 mg Buspirone Hydrochloride Tablets by TEVA Pharmaceuticals Industries, Ltd. with that of 30 mg BUSPAR® Tablets by Bristol-Myers Squibb Company following a single oral dose (1 x 30 mg tablet) in healthy adult volunteers under non-fasting conditions.
Timeline
- Start
- 2001-12
- Primary completion
- 2001-12
- Completion
- 2001-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Buspirone | Small molecule | 30 mg | Oral |
Indications
No indication recorded.